Increased expression of CD70 in relapsed acute myeloid leukemia after hypomethylating agents

Mario L. Marques-Piubelli; Bijender Kumar; Rafet Basar; Siler Panowski; Surabhi Srinivasan; Kevin Norwood; Sacha Prashad; Victoria Szenes; Arun Balakumaran; Akanksha Arandhya; Wei Lu; Khaja Khan; Daniela Duenas; Salome McAllen; Javier A. Gomez; Jared K. Burks; Sunil Acharyal; Gautam Borthakur; Wei Lien Wang; Wei Wang; Sa Wang; Luisa M. Solis; David Marin; Katayoun Rezvani; May Daher; Francisco Vega

doi:10.1007/s00428-024-03741-8

Increased expression of CD70 in relapsed acute myeloid leukemia after hypomethylating agents

Mario L. Marques-Piubelli, Bijender Kumar, Rafet Basar, Siler Panowski, Surabhi Srinivasan, Kevin Norwood, Sacha Prashad, Victoria Szenes, Arun Balakumaran, Akanksha Arandhya, Wei Lu, Khaja Khan, Daniela Duenas, Salome McAllen, Javier A. Gomez, Jared K. Burks, Sunil Acharyal, Gautam Borthakur, Wei Lien Wang, Wei WangSa Wang, Luisa M. Solis, David Marin, Katayoun Rezvani, May Daher, Francisco Vega

Research output: Contribution to journal › Article › peer-review

2 Scopus citations

Abstract

Acute myeloid leukemia (AML) is the most common acute leukemia in adults. While induction chemotherapy leads to remission in most patients, a significant number will experience relapse. Therefore, there is a need for novel therapies that can improve remission rates in patients with relapsed and refractory AML. CD70 is the natural ligand for CD27 (a member of the TNF superfamily) and appears to be a promising therapeutic target. Consequently, there is considerable interest in developing chimeric antigen receptor (CAR) T-cell therapy products that can specifically target CD70 in various neoplasms, including AML. In this study, we employed routine diagnostic techniques, such as immunohistochemistry and flow cytometry, to investigate the expression of CD70 in bone marrow samples from treatment-naïve and relapsed AML patients after hypomethylating agents (HMA). Also, we evaluated the impact of HMA on CD70 expression and examined CD70 expression in various leukemic cell subsets and normal hematopoietic progenitors.

Original language	English (US)
Pages (from-to)	937-941
Number of pages	5
Journal	Virchows Archiv
Volume	485
Issue number	5
DOIs	https://doi.org/10.1007/s00428-024-03741-8
State	Published - Nov 2024

Keywords

CD70
HMA
relapsed acute myeloid leukemia
routine diagnostic technique

ASJC Scopus subject areas

Pathology and Forensic Medicine
Molecular Biology
Cell Biology

Access to Document

10.1007/s00428-024-03741-8

Cite this

Marques-Piubelli, M. L., Kumar, B., Basar, R., Panowski, S., Srinivasan, S., Norwood, K., Prashad, S., Szenes, V., Balakumaran, A., Arandhya, A., Lu, W., Khan, K., Duenas, D., McAllen, S., Gomez, J. A., Burks, J. K., Acharyal, S., Borthakur, G., Wang, W. L., ... Vega, F. (2024). Increased expression of CD70 in relapsed acute myeloid leukemia after hypomethylating agents. Virchows Archiv, 485(5), 937-941. https://doi.org/10.1007/s00428-024-03741-8

Marques-Piubelli, ML, Kumar, B , Basar, R, Panowski, S, Srinivasan, S, Norwood, K, Prashad, S, Szenes, V, Balakumaran, A, Arandhya, A, Lu, W, Khan, K, Duenas, D, McAllen, S, Gomez, JA, Burks, JK, Acharyal, S, Borthakur, G , Wang, WL , Wang, W , Wang, S , Solis, LM , Marin, D , Rezvani, K , Daher, M & Vega, F 2024, 'Increased expression of CD70 in relapsed acute myeloid leukemia after hypomethylating agents', Virchows Archiv, vol. 485, no. 5, pp. 937-941. https://doi.org/10.1007/s00428-024-03741-8

@article{d9f036bb79714347a939bd8f0cbae653,

title = "Increased expression of CD70 in relapsed acute myeloid leukemia after hypomethylating agents",

abstract = "Acute myeloid leukemia (AML) is the most common acute leukemia in adults. While induction chemotherapy leads to remission in most patients, a significant number will experience relapse. Therefore, there is a need for novel therapies that can improve remission rates in patients with relapsed and refractory AML. CD70 is the natural ligand for CD27 (a member of the TNF superfamily) and appears to be a promising therapeutic target. Consequently, there is considerable interest in developing chimeric antigen receptor (CAR) T-cell therapy products that can specifically target CD70 in various neoplasms, including AML. In this study, we employed routine diagnostic techniques, such as immunohistochemistry and flow cytometry, to investigate the expression of CD70 in bone marrow samples from treatment-na{\"i}ve and relapsed AML patients after hypomethylating agents (HMA). Also, we evaluated the impact of HMA on CD70 expression and examined CD70 expression in various leukemic cell subsets and normal hematopoietic progenitors.",

keywords = "CD70, HMA, relapsed acute myeloid leukemia, routine diagnostic technique",

author = "Marques-Piubelli, {Mario L.} and Bijender Kumar and Rafet Basar and Siler Panowski and Surabhi Srinivasan and Kevin Norwood and Sacha Prashad and Victoria Szenes and Arun Balakumaran and Akanksha Arandhya and Wei Lu and Khaja Khan and Daniela Duenas and Salome McAllen and Gomez, {Javier A.} and Burks, {Jared K.} and Sunil Acharyal and Gautam Borthakur and Wang, {Wei Lien} and Wei Wang and Sa Wang and Solis, {Luisa M.} and David Marin and Katayoun Rezvani and May Daher and Francisco Vega",

note = "Publisher Copyright: {\textcopyright} The Author(s) 2024.",

year = "2024",

month = nov,

doi = "10.1007/s00428-024-03741-8",

language = "English (US)",

volume = "485",

pages = "937--941",

journal = "Virchows Archiv",

issn = "0945-6317",

publisher = "Springer Science and Business Media Deutschland GmbH",

number = "5",

}

TY - JOUR

T1 - Increased expression of CD70 in relapsed acute myeloid leukemia after hypomethylating agents

AU - Marques-Piubelli, Mario L.

AU - Kumar, Bijender

AU - Basar, Rafet

AU - Panowski, Siler

AU - Srinivasan, Surabhi

AU - Norwood, Kevin

AU - Prashad, Sacha

AU - Szenes, Victoria

AU - Balakumaran, Arun

AU - Arandhya, Akanksha

AU - Lu, Wei

AU - Khan, Khaja

AU - Duenas, Daniela

AU - McAllen, Salome

AU - Gomez, Javier A.

AU - Burks, Jared K.

AU - Acharyal, Sunil

AU - Borthakur, Gautam

AU - Wang, Wei Lien

AU - Wang, Wei

AU - Wang, Sa

AU - Solis, Luisa M.

AU - Marin, David

AU - Rezvani, Katayoun

AU - Daher, May

AU - Vega, Francisco

PY - 2024/11

Y1 - 2024/11

N2 - Acute myeloid leukemia (AML) is the most common acute leukemia in adults. While induction chemotherapy leads to remission in most patients, a significant number will experience relapse. Therefore, there is a need for novel therapies that can improve remission rates in patients with relapsed and refractory AML. CD70 is the natural ligand for CD27 (a member of the TNF superfamily) and appears to be a promising therapeutic target. Consequently, there is considerable interest in developing chimeric antigen receptor (CAR) T-cell therapy products that can specifically target CD70 in various neoplasms, including AML. In this study, we employed routine diagnostic techniques, such as immunohistochemistry and flow cytometry, to investigate the expression of CD70 in bone marrow samples from treatment-naïve and relapsed AML patients after hypomethylating agents (HMA). Also, we evaluated the impact of HMA on CD70 expression and examined CD70 expression in various leukemic cell subsets and normal hematopoietic progenitors.

AB - Acute myeloid leukemia (AML) is the most common acute leukemia in adults. While induction chemotherapy leads to remission in most patients, a significant number will experience relapse. Therefore, there is a need for novel therapies that can improve remission rates in patients with relapsed and refractory AML. CD70 is the natural ligand for CD27 (a member of the TNF superfamily) and appears to be a promising therapeutic target. Consequently, there is considerable interest in developing chimeric antigen receptor (CAR) T-cell therapy products that can specifically target CD70 in various neoplasms, including AML. In this study, we employed routine diagnostic techniques, such as immunohistochemistry and flow cytometry, to investigate the expression of CD70 in bone marrow samples from treatment-naïve and relapsed AML patients after hypomethylating agents (HMA). Also, we evaluated the impact of HMA on CD70 expression and examined CD70 expression in various leukemic cell subsets and normal hematopoietic progenitors.

KW - CD70

KW - HMA

KW - relapsed acute myeloid leukemia

KW - routine diagnostic technique

UR - http://www.scopus.com/inward/record.url?scp=85185680930&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85185680930&partnerID=8YFLogxK

U2 - 10.1007/s00428-024-03741-8

DO - 10.1007/s00428-024-03741-8

M3 - Article

C2 - 38388965

AN - SCOPUS:85185680930

SN - 0945-6317

VL - 485

SP - 937

EP - 941

JO - Virchows Archiv

JF - Virchows Archiv

IS - 5

ER -

Increased expression of CD70 in relapsed acute myeloid leukemia after hypomethylating agents

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this